Payment overview · 2025
General Payments
$132.26
8 reported records · 4 companies
Healthcare provider profile · identity verified
Taylor S Long, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JONESBORO, AR · NPI 1326655416
Verified facts
What the public records show
CMS Open Payments records show Taylor S Long, FNP received $132.26 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.37 | 35.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.91 | 27.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.79 | 23.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.19 | 13.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $132.26 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.37 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 77 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 66 |
| Metformin Hcl | Metformin Hcl | 225 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 66 |
| Gabapentin | Gabapentin | 196 | 50 |
| Lisinopril | Lisinopril | 195 | 65 |
| Furosemide | Furosemide | 192 | 59 |
| Omeprazole | Omeprazole | 179 | 49 |
| Meloxicam | Meloxicam | 157 | 45 |
| Jardiance | Empagliflozin | 150 | 45 |
| Ozempic | Semaglutide | 144 | 32 |
| Carvedilol | Carvedilol | 143 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 38 |
| Potassium Chloride | Potassium Chloride | 134 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 55 |
| Losartan Potassium | Losartan Potassium | 109 | 26 |
| Ezetimibe | Ezetimibe | 108 | 32 |
| Spironolactone | Spironolactone | 103 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 25 |
| Trazodone Hcl | Trazodone Hcl | 98 | 29 |
| Farxiga | Dapagliflozin Propanediol | 94 | 25 |
| Allopurinol | Allopurinol | 93 | 19 |
| Prednisone | Prednisone | 89 | 60 |
| Glipizide Er | Glipizide | 87 | 30 |
| Alprazolam | Alprazolam | 85 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 26 |
| Mounjaro | Tirzepatide | 81 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 23 |
| Gemtesa | Vibegron | 77 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 21 |
| Famotidine | Famotidine | 74 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 16 |
| Azithromycin | Azithromycin | 64 | 55 |
| Simvastatin | Simvastatin | 64 | 23 |
| Eliquis | Apixaban | 63 | 17 |
| Montelukast Sodium | Montelukast Sodium | 61 | 19 |
| Atenolol | Atenolol | 60 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 17 |
| Clonazepam | Clonazepam | 52 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 17 |
| Pregabalin | Pregabalin | 49 | 12 |
| Ondansetron Odt | Ondansetron | 48 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 18 |
| Entresto | Sacubitril/Valsartan | 45 | 15 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 13 |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 28 |
| Sotalol | Sotalol Hcl | 36 | 12 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 14 |
| Buspirone Hcl | Buspirone Hcl | 34 | 12 |
| Nystatin | Nystatin | 34 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 29 |
| Linzess | Linaclotide | 31 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 24 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 16 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | 11 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132.26 · 8 records | GlaxoSmithKline, LLC. | GEMTESA, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error